Abstract
The 5-HT1A receptor has been extensively studied over the last two decades. There is a plethora of information describing its anatomical, physiological and biochemical roles in the brain. In addition, the development of selective pharmacological tools coupled with our understanding of psychiatric pathology has lead to multiple hypotheses for the therapeutic utility of 5-HT1A agents and in particular 5-HT1A receptor antagonists. Over the last decade it has been suggested that 5-HT1A receptor antagonists may have therapeutic utility in such diseases as depression, anxiety, drug and nicotine withdrawal as well as schizophrenia. However, a very compelling rationale has been developed for the therapeutic potential of 5-HT1A receptor antagonists in Alzheimers disease and potentially other diseases with associated cognitive dysfunction. Receptor blockade by a 5-HT1A receptor antagonist appears to enhance activation and signaling through heterosynaptic neuronal circuits known to be involved in cognitive p rocesses and, as such, represents a novel therapeutic approach to the treatment of cognitive deficits associated with Alzheimers disease and potentially other disorders with underlying cognitive dysfunction.
Keywords: 5-HT1A Receptor Antagonists, Alzheimers Disease
Current Pharmaceutical Design
Title: The Potential Utility of 5-HT1A Receptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimers Disease
Volume: 8 Issue: 2
Author(s): L. E. Schechter, L. A. Dawson and J. A. Harder
Affiliation:
Keywords: 5-HT1A Receptor Antagonists, Alzheimers Disease
Abstract: The 5-HT1A receptor has been extensively studied over the last two decades. There is a plethora of information describing its anatomical, physiological and biochemical roles in the brain. In addition, the development of selective pharmacological tools coupled with our understanding of psychiatric pathology has lead to multiple hypotheses for the therapeutic utility of 5-HT1A agents and in particular 5-HT1A receptor antagonists. Over the last decade it has been suggested that 5-HT1A receptor antagonists may have therapeutic utility in such diseases as depression, anxiety, drug and nicotine withdrawal as well as schizophrenia. However, a very compelling rationale has been developed for the therapeutic potential of 5-HT1A receptor antagonists in Alzheimers disease and potentially other diseases with associated cognitive dysfunction. Receptor blockade by a 5-HT1A receptor antagonist appears to enhance activation and signaling through heterosynaptic neuronal circuits known to be involved in cognitive p rocesses and, as such, represents a novel therapeutic approach to the treatment of cognitive deficits associated with Alzheimers disease and potentially other disorders with underlying cognitive dysfunction.
Export Options
About this article
Cite this article as:
Schechter E. L., Dawson A. L. and Harder A. J., The Potential Utility of 5-HT1A Receptor Antagonists in the Treatment of Cognitive Dysfunction Associated with Alzheimers Disease, Current Pharmaceutical Design 2002; 8 (2) . https://dx.doi.org/10.2174/1381612023396483
DOI https://dx.doi.org/10.2174/1381612023396483 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Relationship Between Epilepsy and Depression: An Update
Current Medicinal Chemistry Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands
Current Medicinal Chemistry The Effects of Gender and CYP46 and Apo E Polymorphism on 24S-Hydroxycholesterol Levels in Alzheimers Patients Treated with Statins
Current Alzheimer Research Commentary : Hypothesis Focused Ultrasound and NXY-059 in Experimental Cerebral Ischemia: A New Therapeutic Opportunity?
CNS & Neurological Disorders - Drug Targets An Overview of Recent Patents on Oral Osmotic Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease
Current Alzheimer Research Vilazodone Hydrochloride Multi-dose Nasal Spray Solution for the Treatment of Depression: Design, Optimization and Evaluation
Current Drug Therapy Triple Threat: The Na+/Ca2+ Exchanger in the Pathophysiology of Cardiac Arrhythmia, Ischemia and Heart Failure
Current Drug Targets Poly-Pharmacy Among the Elderly: Analyzing the Co-Morbidity of Hypertension and Diabetes
Current Pharmaceutical Design Paresthesia: A Review of Its Definition, Etiology and Treatments in View of the Traditional Medicine
Current Pharmaceutical Design The HGF-Met Signaling Axis: Emerging Themes and Targets of Inhibition
Current Protein & Peptide Science Cannabinoid System in Neurodegeneration: New Perspectives in Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Elective Cesarean Section- the Right Choice for Whom?
Current Women`s Health Reviews Patent Selections
Recent Patents on DNA & Gene Sequences Can Topiramate Induce Pruritus? A Case Report and Review of Literature
CNS & Neurological Disorders - Drug Targets MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology
Current Neuropharmacology Microvascular Alterations in Hypertension and Vascular Aging
Current Hypertension Reviews Treatment of Alzheimers Disease: The Beginning of a New Era Dale Schenk, ISOA - October 5th-6th, 2005
Current Alzheimer Research Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management
Current Diabetes Reviews Morphofunctional Aspects of the Blood-Brain Barrier
Current Drug Metabolism